Motley Fool Wealth Management LLC Cuts Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Motley Fool Wealth Management LLC trimmed its holdings in Moderna, Inc. (NASDAQ:MRNA) by 16.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 155,388 shares of the company’s stock after selling 31,583 shares during the period. Motley Fool Wealth Management LLC’s holdings in Moderna were worth $6,190,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in MRNA. State Street Corp grew its stake in Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares in the last quarter. Amundi increased its holdings in shares of Moderna by 79.8% in the fourth quarter. Amundi now owns 1,206,273 shares of the company’s stock worth $52,075,000 after purchasing an additional 535,273 shares during the last quarter. Two Sigma Advisers LP purchased a new stake in shares of Moderna in the third quarter worth about $23,825,000. Finally, Douglas Lane & Associates LLC boosted its stake in Moderna by 62.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after buying an additional 298,715 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $33.85 on Wednesday. The business’s 50-day moving average is $34.87 and its 200 day moving average is $45.12. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47. The firm has a market capitalization of $13.09 billion, a P/E ratio of -3.65 and a beta of 1.86.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Bank of America decreased their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a report on Tuesday, February 11th. Morgan Stanley dropped their price objective on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. Royal Bank of Canada restated a “sector perform” rating and set a $40.00 target price on shares of Moderna in a research report on Tuesday, February 18th. JPMorgan Chase & Co. dropped their price target on Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research report on Friday, March 21st. Finally, The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and cut their target price for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus target price of $59.00.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.